Navigation Links
Odyssey Thera Granted U.S. Patent for Animal Imaging
Date:12/12/2007

SAN RAMON, Calif., Dec. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation Assays (PCA) in whole animals: applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy." This is the twelfth patent issued for Odyssey Thera's PCA process.

The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at Odyssey Thera to monitor drug response. The invention makes it possible to monitor specific biochemical parameters, including the extent and kinetics of drug target modulation, in a live subject.

"This patent extends our broad estate in drug discovery technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "One of the most challenging aspects of drug discovery is transitioning drug candidates from the test tube, to native targets in living cells, and from there to live subjects. With this invention, drug discovery and development are achieved with a single system that faithfully monitors the activity of a drug at each step." Dr. Westwick continues, "Whole animal studies using fluorescence or luminescence detection are widely used in the pharmaceutical industry, but strategies were needed to increase the scope of biochemical activities that can be tracked. The approaches described here will significantly increase the value of live subject imaging efforts."

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for chronic diseases. Odyssey Thera is leveraging its proprietary pathway-based approach and human cell models to optimize drug development for its own programs and for its premier pharmaceutical company partners.

To learn more about Odysse
'/>"/>

SOURCE Odyssey Thera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quorum Review IRB, the industry ... large clinical trials called Quick Step™ . The offering ... address the research industry’s need for seamless study start-up with ... available for studies planning 50 or more North American investigator ... North American site count of 80 or more. Qualifying studies ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
(Date:7/21/2014)... IL (PRWEB) July 21, 2014 ... and simple programming, the new Cole-Parmer® Digital ... is easy to operate for automated process ... for hands-free dispensing. The batch count function counts ... volume or totalizer tracks amount dispensed across multiple ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... (Nasdaq: WHRT, TSX:,WHT) Since January 2008, ... various financing alternatives to raise additional,capital, including ... order to continue operations. At April 30, ... of approximately $0.5 million and,current liabilities of ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... final approval from the U.S. Food and Drug,Administration ... to,manufacture and market a generic version of Yasmin(R) ... and marketed,by Bayer Schering Pharma, AG., On ...
... KENILWORTH, N.J., May 9 Schering-Plough,Corporation (NYSE: SGP ... 16, 2008, in Memphis, Tenn. At 8 a.m. (CDT) ... the meeting will be available to all interested,parties via ... the Annual Meeting, Fred Hassan, Chairman and CEO, will ...
Cached Biology Technology:WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 2WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 3WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 4Barr Announces Approval of Generic Yasmin(R) 2Barr Announces Approval of Generic Yasmin(R) 3
(Date:7/22/2014)... challenges faced by researchers in modifying properties of nanomaterials ... simple technique, thanks to recent innovative studies conducted by ... Through the use of a simple, efficient and low ... research teams, led by Professor Sow Chorng Haur from ... Science, demonstrated that the properties of two different types ...
(Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
(Date:7/22/2014)... NY -- As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature , point to biological ... lead to new approaches to treating the disorder, which ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3
... New combinations of agents based on the oldest synthetic ... spread of malaria parasites and make a significant contribution ... "Roll Back Malaria Initiative." In a study on 160 ... medicine from the Heidelberg University Hospital have shown that ...
... Wash. -- Some researchers hope to turn plants into ... this, scientists have to learn how to convert plant ... cheaply and efficiently. In new research, chemists have successfully ... directly into the building block called HMF in one ...
... Individuals with heart disease are twice as likely to ... the medical community has largely been unable to explain. ... Hospital, in conjunction with The Montral Heart Institute, University ... genetic variations that contribute to depression in heart disease ...
Cached Biology News:Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2Genetic factors may predict depression in heart disease patients 2Genetic factors may predict depression in heart disease patients 3
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Biology Products: